2020 BioTech Life Science 
Healthcare IT Today
OCTOBER 24, 2024
In addition, MDisrupt will add new features to the marketplace platform through a strategic collaboration with the Association to meet the needs of its members, providing new ways for them to engage with the health technology, health services, medical device, and life sciences sectors.
Health Populi
MAY 20, 2021
in the first quarter of 2020. The first chart from the Edelman health care update demonstrates that in most countries polled, health citizens’ trust in health care was buoyed in the first five months of 2020 (January through May): up 18 points in the U.S., Consumer health’s fall from 63% in 2019 to 51% in 2020.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
FEBRUARY 24, 2020
health citizens’ minds in 2020 leading up to the election. And note how Americans’ trust in hospitals — historically the top-trusted health care segment in the nation — eroded from 2018, tying with consumer health companies, and just north of biotech and life science organizations.
Health Populi
JUNE 24, 2021
While telehealth and virtual care stood up quickly in 2020, questions remain about how it will/can persist in terms of funding, regulation, and business models. We also expect innovation to come out of pharma and biotech labs, and who will pay for new-new therapies?
Health Populi
MARCH 11, 2021
have struggled to pay for living expenses since December 2020, a year into the COVID-19 pandemic. Speaking of design, this Summit was indeed well-designed by spotlighting pragmatic representatives from these various stakeholder groups.
Health Populi
SEPTEMBER 1, 2020
in May and June 2020. That six in ten oncologists perceived patient access programs are helpful in the pandemic is important because new oncologics launched in 2020 can be priced an average of $149,000 according to the 2019 forecast from IQVIA. Financial toxicity is a common side-effect for specialty drugs, and as U.S.
Digital Health Global
NOVEMBER 30, 2023
in 2020, with projections suggesting up to 70% of clinical trials incorporating wearable sensors by 2025. AstraZeneca has launched Evinova , an healthtech business focusing on providing digital solutions for clinical trials in the life sciences sector. In a recent review paper appeared on Nature , Mittermaier et al.
Expert insights. Personalized for you.
124 
Let's personalize your content